top of page
2017年　業績

欧文原著

１．Kikuchi H, Sakakibara-Konishi J, Furuta M, Yokouchi H, Nishihara H, Yamazaki S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Harada T, Higuchi M, Honjo O, Minami Y, Watanabe N, Oizumi S, Suzuki H, Ishida T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M. Expression of Notch1 and Numb in small cell lung cancer. Oncotarget. 8(6):10348-10358, 2017.

 

２．Pham TD, Watanabe Y, Higuchi M, Suzuki H. Texture Analysis and Synthesis of Malignant and Benign Mediastinal Lymph Nodes in Patients with Lung Cancer on Computed Tomography. Sci Rep. 7:43209, 2017.

 

３．Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Goto A, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M. Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker. Oncotarget. 8(24): 39711-39726, 2017

 

４．Saito M, Suzuki H, Kono K, Takenoshita S, Kohno T. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today. [Epub ahead of print]

 

５．Higuchi M, Takagi H, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, Yonechi A, Osugi J, Hoshino M, Shio Y, Fujiu K, Kanno R, Ohishi A, Suzuki H, Gotoh M. Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons. Oncol Lett 13 :4315-4321, 2017

 

６．Muto S, Takagi H, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Suzuki H. Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients. Anticancer Res 37 (6) 3169-3174, 2017

 

７．Fukuhara M, Higuchi M, Owada Y, Inoue T, Watanabe Y, Yamaura T, Muto S, Hasegawa T, Suzuki H. Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports. Journal of Thoracic Disease 9(6):1592-1597, 2017.

 

８．Matsumura Y, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Hasegawa T, Hoshino M, Osugi J, Higuchi M, Suzuki H. Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinomaInteractive. Interactive CardioVascular and Thoracic Surgery. ivx207, 2017.

 

９．Mai T, Takano A, Suzuki H, Hirose T, Mori T, Teramoto K, Kiyotani K, Nakamura Y, Daigo Y. Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine. Oncol Lett. 14(1): 283-292, 2017.

 

１０．Matsumura Y, Suzuki H, Ohira T, Shiono S, Abe J, Sagawa M, Sakurada A, Katahira M, Machida Y, Takahashi S, Okada Y. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma. Lung Cancer. 114; 23-30, 2017.

 

１１．Okabe N, Takagi H, Mine H, Fukai S, Minemura H, Suzuki H. Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma. Journal of Thoracic Oncology 12(10): e155-e173, 2017.

 

１２．Inoue T, Takagi H, Owada Y, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Yokouchi H, Kanazawa K, Ohbuchi K, Fukushima T, Munakata M, Suzuki H. Efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial. Trials. 18:485, 2017

 

１３．Yamaura T, Ezaki J, Okabe N, Takagi H, Ozaki Y, Inoue T, Watanabe Y, Fukuhara M, Muto S, Matsumura Y, Hasegawa T, Hoshino M, Osugi J, Shio Y, Waguri S, Tamura H, Imai J, Ito E, Yanagisawa Y, Honma R, Watanabe S, Suzuki H. Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor. Oncology Letters. In press

 

 

欧文総説

  1. Higuchi M, Nemoto T, Matsuida H, Oshibe I, Soeta N, Takeshige T, Saito T, Suzuki H. Current status and future prospects of PET/CT in NSCLC treated with checkpoint-based immunotherapy. J Rare Dis Res Treat. 2(2): 43-49, 2017

 

 

和文原著

  1. 樋口光徳, 大和田有紀, 井上卓哉, 渡邊　譲, 山浦　匠, 福原光朗, 武藤哲史, 長谷川剛生, 鈴木弘行. 胸腺癌手術症例の術後成績. 日本呼吸器外科学会雑誌 31(2): 148-154, 2017.

 

 

和文総説

  1. 武藤哲史, 鈴木弘行. 【特集】胸部外科領域における合併症予防のための周術期管理　肺切除手術後の胸腔ドレーン管理の要点. 胸部外科 70(8): 683-687, 2017

 

２．鈴木弘行, 髙木玄教, 大和田有紀, 渡邊　譲, 井上卓哉, 福原光朗, 山浦　匠, 武藤哲史, 岡部直行, 長谷川剛生, 塩　　豊. 肺がんに対する免疫療法の歴史とがんワクチン療法. 癌と化学療法 44(8): 646-649, 2017

 

３．大和田有紀, 井上卓哉, 渡邊　譲, 福原光朗, 山浦　匠, 武藤哲史, 松村勇輝, 長谷川剛生, 田中大輔, 菅野　亮, 伊藤恵美, 七宮英晃, 今井順一, 磯貝隆夫, 渡辺慎哉, 鈴木弘行. 非小細胞肺癌における免疫チェックポイント阻害薬の新たなバイオマーカー抽出の可能性. 癌と化学療法 44(9): 763 -766, 2017

bottom of page